Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Glycerol phenylbutyrate
Clinical data | |
---|---|
Trade names | Ravicti |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
License data | |
Routes of administration |
By mouth |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.228.552 |
Chemical and physical data | |
Formula | C33H38O6 |
Molar mass | 530.661 g·mol−1 |
3D model (JSmol) | |
| |
|
Glycerol phenylbutyrate (USAN), trade name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body. It is an FDA-approved prescription drug in the US. It is approved for anyone over 2 months of age. It was developed by Hyperion Therapeutics based on the existing drug Buphenyl, and received approval on February 1, 2013. Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000–290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl ($113.6 million in sales). In March 2015, Horizon Pharma acquired Hyperion Therapeutics and thus Raviciti.
External links
- "Glycerol phenylbutyrate". Drug Information Portal. U.S. National Library of Medicine.